Feyisa Seifu Gizaw, Abdurahman Ahmed Abdulahi, Jimma Worku, Chaka Eshetu Ejeta, Kardan-Yamchi Jalil, Kazemian Hossein
Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, International Campus, Tehran, Iran.
Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Heliyon. 2019 Jan 1;5(1):e01081. doi: 10.1016/j.heliyon.2018.e01081. eCollection 2019 Jan.
Antitubercular drug resistance strain is a horrifying barrier to effective TB treatment and prevention. The present study aimed to determine the prevalence and geographical distribution of rifampicin-resistance (MTB) strains.
We searched two electronic databases, PubMed and EMBASE, until 26 March 2017 and updated our search on 27 April 2018 and accessed all prevalence studies of MTB strain and their drug susceptibility patterns to rifampicin. The pooled prevalence estimate was determined using random effects model.
We identified 23 studies satisfying the inclusion criteria. The proportion of rifampicin resistance strains was diverged depending on the type of strains, country and Regions. The pooled estimate of rifampicin-resistance strains of MTB for the included studies was 4% (95% CI: 3-5%). In subgroup analysis based on World Health Organization (WHO) Regions, the pooled estimate of rifampicin-resistance strains of MTB was 11% (95% CI: 9-13%) with the Western Pacific Region 24%, Europian Region 10%, South-East Asian Region 6%, African Region 3% and Region of American 1%. Beijing family was the most dominant strain resistance to rifampicin with pooled prevalence of 14% (95% CI: 10-18%). The pooled prevalence of other families, i.e. EAI, T, CAS, MANU, Haarlem, LAM and Ural, was ≤2% for each.
High burden of rifampicin resistance MTB strains was identified in the Western Pacific Region. Of these, Beijing family was predominantly resistance to rifampicin in Western Pacific Region and South-East Asian Region and also spread to European Region and Region of American.
耐抗结核药物菌株是有效治疗和预防结核病的可怕障碍。本研究旨在确定利福平耐药（MTB）菌株的流行情况和地理分布。
我们检索了两个电子数据库，即PubMed和EMBASE，检索截至2017年3月26日，并于2018年4月27日更新检索，获取了所有关于MTB菌株及其对利福平药物敏感性模式的患病率研究。使用随机效应模型确定合并患病率估计值。
我们确定了23项符合纳入标准的研究。利福平耐药菌株的比例因菌株类型、国家和地区而异。纳入研究中MTB利福平耐药菌株的合并估计值为4%（95%CI：3 - 5%）。在基于世界卫生组织（WHO）区域的亚组分析中，MTB利福平耐药菌株的合并估计值为11%（95%CI：9 - 13%），其中西太平洋区域为24%，欧洲区域为10%，东南亚区域为6%，非洲区域为3%，美洲区域为1%。北京家族是对利福平耐药最主要的菌株，合并患病率为14%（95%CI：10 - 18%）。其他家族，即EAI、T、CAS、MANU、哈勒姆、LAM和乌拉尔家族的合并患病率均≤2%。
西太平洋区域确定了高负担的利福平耐药MTB菌株。其中，北京家族在西太平洋区域和东南亚区域主要对利福平耐药，并且也传播到了欧洲区域和美洲区域。
